Cardiff Lexington ($CDIX) Director Granted 50,000 Stock Options
Cardiff Lexington Corp
Filing Summary
Cardiff Lexington ($CDIX) Director Granted Equity Awards
Company: Cardiff Lexington Corp (CDIX) Form: 4 | Filed: 2025-12-15 Significance: Medium
Insider: Johnson Gillard B. III Title: null | Relationship: Director
Transaction Summary: • Type: Grant (Stock & Options) • Securities: 10,000 shares & 50,000 options • Price: $0.00 (for the grant) • Value: $0 (grant value) • Owned After: 20,000 shares & 50,000 options
Key Insight: A director received a significant equity compensation package including shares and options, aligning their interests with shareholders. The options have an exercise price of $1.729.
Market Context: These are compensation-related grants, not open-market purchases. The filing was submitted after the regulatory deadline for the transaction dates (Sept 26 & Dec 11).
This is PUBLIC SEC data for educational purposes. Not investment advice.
Comprehensive Analysis
SEC Filing Analysis: Cardiff Lexington Corp (CDIX)
Executive Summary
- Trading Significance: Medium
- Key Takeaway: A director, Gillard B. Johnson III, received a substantial equity compensation package consisting of 10,000 shares of common stock and 50,000 stock options.
- Market Impact: Neutral. These are compensation-related grants, not open-market transactions, and thus do not serve as a strong market signal.
Company Information
| Field | Value |
|---|---|
| Company | Cardiff Lexington Corp |
| Ticker Symbol | CDIX |
| CIK | 0000811222 |
| Industry | Services-Offices & Clinics of Doctors of Medicine |
Insider Information
| Field | Value |
|---|---|
| Name | Johnson Gillard B. III |
| CIK | 0002020536 |
| Title/Position | null |
| Relationship | Director |
Transaction Details
This filing reported three separate grant transactions:
| Field | Transaction 1 | Transaction 2 | Transaction 3 |
|---|---|---|---|
| Transaction Date | 2025-09-26 | 2025-09-26 | 2025-12-11 |
| Form Type | 4 | 4 | 4 |
| Transaction Code | A (Award) | A (Award) | A (Award) |
| Security Type | Common Stock | Common Stock | Stock Option |
| Shares Involved | 5,000 | 5,000 | 50,000 |
| Price Per Share | $0.00 | $0.00 | $0.00 |
| Total Value | $0 | $0 | $0 |
| Ownership Type | Direct | Direct | Direct |
Financial Impact Assessment
Impact Evaluation
Without market capitalization or shares outstanding data, a quantitative assessment of materiality is not possible. Qualitatively, the grants serve to align the director's interests with those of shareholders. The 50,000 stock options have an exercise price of $1.729, creating an incentive for the director to contribute to share price appreciation above this level. The total package increases the director's direct stake in the company, strengthening this alignment.
Market Impact Analysis
Stock Impact Prediction
- Direction: Neutral
- Reasoning: The transactions are grants as part of a compensation plan, not open-market buys or sells reflecting an insider's current market sentiment. Such events are standard corporate governance practice and are not typically interpreted as strong trading signals.
Volume & Sentiment
- Expected Volume Impact: Low. No shares were traded on the open market; this was an issuance from the company's equity incentive plan.
- Sentiment Indicator: Neutral. The grants are a positive sign of long-term alignment but do not provide new information about the company's immediate prospects.
Investment Insights
Positive Market Indicators
- Insider Alignment: The grants increase the director's skin in the game, which is generally viewed positively by investors.
Risk Factors
- Potential Dilution: The issuance of 10,000 new shares and the potential future exercise of 50,000 options will result in dilution for existing shareholders.
- Late Filing: The transactions occurred on September 26 and December 11, but the Form 4 was not filed until December 15, indicating a delay in reporting.
Key Takeaways
- A director received a compensation package of 10,000 common shares and 50,000 stock options.
- The stock option grant has an exercise price of $1.729 and a 10-year expiration.
- The transactions are non-market compensation events and carry a neutral sentiment.
Additional Context
Transaction Notes
- Vesting Schedules: The grants are subject to vesting conditions as detailed in the footnotes.
- 5,000 shares vested in full on the grant date (Sept 26, 2025).
- 5,000 shares have a quarterly vesting schedule over three quarters.
- 50,000 options have a quarterly vesting schedule over four quarters starting January 1, 2026.
- Source: All grants were made under the Issuer's 2024 Equity Incentive Plan.
Important Disclaimer
This analysis is for informational and educational purposes only and is NOT investment advice.
The information presented is based on publicly available SEC filings and should not be construed as a recommendation to buy, sell, or hold any securities. Past performance does not guarantee future results. All investments carry risk, including the potential loss of principal.
Always consult with a qualified financial advisor before making any investment decisions.
Data Sources:
- SEC EDGAR Filings (Official)
- Analysis Generated: 2025-12-15
Join Our Community:
- 💬 Discord Community - Real-time alerts & discussions
- 📊 View Original SEC Filing
This post is automated and based on publicly available SEC EDGAR filings. All data is sourced directly from official SEC databases.
Get Real-Time Alerts
Join our community to receive instant notifications when high-significance filings are published
⚠️ Important Disclaimer
This analysis is based on PUBLIC SEC data and is provided for educational and informational purposes ONLY. This is NOT investment advice, financial advice, or a recommendation to buy, sell, or hold any securities. The information presented should not be construed as a recommendation to take any action regarding any securities.
Past performance does not guarantee future results. All investments carry risk, including the potential loss of principal. Please consult with a qualified financial advisor before making any investment decisions.